50th anniversary of the discovery of ibuprofen: An interview with Dr Stewart Adams

Platelets

Volumn 23, Issue 6, 2012, Pages 415-422

  Halford, Gayle M ^a   Lordkipanidzé, Marie ^a   Watson, Steve P ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cyclooxygenase inhibitor; Ibuprofen; Non Steroidal Anti Inflammatory Drugs; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; BTS 10335; BTS 10499; BTS 8402; HEPARIN; HISTAMINE; HYDROCORTISONE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLATE SODIUM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AWARDS AND PRIZES; CHEMISTRY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESEARCH; ERYTHEMA; EXPERIMENTAL GUINEA PIG; HUMAN; INTERVIEW; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCIENTIST; WORK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DRUG DISCOVERY; GREAT BRITAIN; HISTORY, 20TH CENTURY; IBUPROFEN;

EID: 84864846872     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.632032     Document Type: Review

References (41)

1. Ligon BL. Penicillin: Its discovery and early development. Semin Pediatr Infect Dis 2004;15:52-57.
2. Adams SS. Ibuprofen, the propionics and NSAIDs: Personal reflections over four decades. Inflammopharmacology 1999;7:191-197.
3. Adams SS. The propionic acids: A personal perspective. J Clin Pharmacol 1992;32:317-323.
4. Harris SC, Fosdick LS. Theoretical considerations of the mechanisms of antipyretic analgesia. NWU Bull 1952;53:6-9.
5. CORTISONE and aspirin. Br Med J 1955;2:725-726.
6. Mottram PL. Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol 2003;81:350-353.
7. Adams SS, Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs. Nature 1958;181:773-774.
8. Adams SS. Some reflections on ibuprofen. J R Soc Med 2007;100 Suppl 48:1.
9. Wilhelmi G. [Antiphlogistic effect of pyrazols, especially of irgapyrin, in peroral and parenteral administration]. Schweiz Med Wochenschr 1950;80:936-942.
10. Winder CV, Wax J, Burr V, Been M, Rosiere CE. A study of pharmacological influences on ultraviolet erythema in guinea pigs. Arch Int Pharmacodyn Ther 1958;116:261-293.
11. Adams SS. The testing of non-hormonal anti-rheumatic compounds. Research Department Report. No. 848: Boots Pure Drug Co. Ltd, 1956.
12. Adams SS, Bough RG, Cliffe EE, Dickinson W, Lessel B, McCullough KF, Mills RF, Nicholson JS, Williams GA. Some aspects of the pharmacology, metabolism, and toxicology of ibuprofen. I. Pharmacology and metabolism. Rheumatol Phys Med 1970;10:Suppl 10:9-26.
13. Adams SS, Cliffe EE, Lessel B, Nicholson JS. Some biological properties of 2-(4-isoburylphenyl)-propionic acid. J Pharm Sci 1967;56:1686.
14. Mills RF, Adams SS, Cliffe EE, Dickinson W, Nicholson JS. The metabolism of ibuprofen. Xenobiotica 1973;3:589-598.
15. Adams SS, Bough RG, Cliffe EE, Lessel B, Mills RF. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969;15:310-330.
16. Adams SS, McCullough KF, Nicholson JS. The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int Pharmacodyn Ther 1969;178:115-129.
17. Moore N. Ibuprofen: A journey from prescription to overthe-counter use. J R Soc Med 2007;100 Suppl 48:2-6.
18. Mustard JF, Packham MA, Kinlough-Rathbone RL. Non-steroidal anti-inflammatory agents and coronary heart disease. Acta Med Scand Suppl 1980;642:180-190.
19. Baele G, De Weerdt GA, Barbier F. Preliminary results of platelet aggregation before and after administration of ibuprofen. Rheumatol Phys Med 1970;10(Suppl 10):108-111.
20. Ikeda Y. The effect of ibuprofen on platelet function in vivo. Keio J Med 1977;26:213-222.
21. McIntyre BA, Philp RB, Inwood MJ. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther 1978;24:616-621.
22. Lefer AM, Polansky EW. Beneficial effects of ibuprofen in acute myocardial ischemia. Cardiology 1979;64:265-279.
23. Lefer AM, Crossley K. Mechanisms of the optimal protective effects of ibuprofen in acute myocardial ischemia. Adv Shock Res 1980;3:133-141.
24. Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008;47:129-137.
25. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002;359:118-123.
26. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:383-388.
27. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
28. Gengo FM, Rubin L, Robson M, Rainka M, Gengo MF, Mager DE, Bates V. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: Clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008;48:117-122.
29. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-1195.
30. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation 2011;123:2226-2235.
31. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ 2011;342:c7086.
32. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010:CD003481.
33. Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982;306:506-510.
34. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 2010;74:995-1002.
35. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: Systematic review and metaanalysis of observational studies. Drugs Aging 2009;26:769-779.
36. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963-967.
37. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011;76:863-869.
38. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
39. Adams SS. Non-steroidal anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 1987;2:1204-1205.
40. Adams SS. NSAIDs, plasma half-lives, and adverse reactions. Lancet 1988;1:653-654.
41. Rainsford KD. Ibuprofen: Pharmacology, efficacy and safety. Inflammopharmacology 2009;17:275-342